drugset / Trial / NCT00698191

Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)

NCT00698191 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to restore a normal immune system that will no longer attack the body. The stated hypothesis is that the SLE condition is caused by an abnormal immune system that can be restored by replenishing the body with a new population of progenitor cells.

Timeline

Start
2007-03
Primary completion
2011-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic MSC Cell therapy 106 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 0.8 g Intravenous
Background Cyclophosphamide Other / unclassified 1.8 g Intravenous